Published 1981 by U.S. Dept. of Health and Human Services, Public Health Service, National Institutes of Health, National Cancer Institute, For sale by the Supt. of Docs., U.S. G.P.O. in Bethesda, Md, Washington, D.C .
Written in EnglishRead online
|Statement||[prepared by Demographic Analysis Section, Division of Cancer Cause and Prevention, National Cancer Institute ; edited by John L. Young, Jr., Constance L. Percy, Ardyce J. Asire].|
|Series||National Cancer Institute monograph ;, v. 57, NIH publication ;, no. 81-2330, DHHS publication ;, no. (NIH) 81-2330.|
|Contributions||Young, John L., Percy, Constance L., Asire, Ardyce J., National Cancer Institute (U.S.), National Cancer Institute (U.S.). Demographic Analysis Section.|
|LC Classifications||RC261 .A448 no. 57, RC276 .A448 no. 57|
|The Physical Object|
|Pagination||xxii, 1082 p. ;|
|Number of Pages||1082|
|LC Control Number||81603460|
Download Surveillance, epidemiology, and end results
The Surveillance, Epidemiology, and End Results (SEER) Program provides information on cancer statistics in an effort to reduce the cancer burden among the U.S.
population. SEER is supported by the Surveillance Research Program (SRP) in NCI's Division of. SEER (Surveillance, Epidemiology, and End Results Program) Source: Surveillance epidemiology Operations Research Branch, Blair Building, RoomNational Cancer Institute, National Institutes of Health, Bethesda, MDSubject: Cancer surveillance and by: The Surveillance, Epidemiology, and End Results Program: a national resource.
external icon Cancer Epidemiology, Biomarkers and Prevention ;8(12)– Page last reviewed: June 8, Content source: Division of Cancer Prevention and Control, Centers for Disease Control and Prevention.
While the Surveillance, Epidemiology, and End Results Prostate with Watchful Waiting dataset offers a new method to describe treatment trends for men with prostate cancer, including the use of active surveillance, it has a significant amount of missing data, which can be a source of potential bias if not addressed by: 1.
Surveillance, Epidemiology, and End Results (SEER) data indicate age-adjusted incidence rates of to perpersons in the United States. The incidence tripled from toand approximately cases of MCC are diagnosed each year. – MCC is rare in blacks; most patients are white (%). Ninety percent of.
The Surveillance, Epidemiology, and End Results (SEER) program of the National Cancer Institute (NCI) is a source of epidemiologic information on the incidence and survival rates of cancer in the United States. The Program. SEER collects and publishes cancer incidence and survival data from population-based cancer registries covering.
Surveillance, epidemiology, and end results analysis of cases of uterine sarcoma Gynecol Oncol. Apr;93(1) doi: / Authors Sandra E Brooks 1, Min Zhan, Timothy Cote, Claudia R Baquet. Affiliation 1 Department. There were 2, adult patients diagnosed with stage III or IV, M0, hypopharyngeal squamous cell carcinoma identified within the Surveillance, Epidemiology and End Results (SEER) registry (years –).
Options for accessing datasets for incidence, mortality, county populations, standard populations, expected survival, and SEER-linked and specialized data. Plus variable definitions, documentation for reporting and using datasets, statistical software (SEER*Stat), and observational research resources.
Get this from a library. Surveillance, epidemiology, and epidemiology results: incidence and mortality data, [John L Young, Jr.; Constance L Percy; Ardyce J Asire. Methods and Materials: Using the Surveillance, Epidemiology, and End Results (SEER) database, information was obtained for all female patients, ages 20 to 39 years old, diagnosed with T N M0 breast cancer between andwho underwent either BCT (lumpectomy and radiation treatment) or.
Guidelines, tools, and resources for cancer registrars, including coding and staging manuals, glossary, drug database (SEER*Rx), SEER abstracting tool (SEER*Abs), Q&A resources, and training modules for registration and surveillance. Also read SEER announcements or join e-mail list.
NCI's Surveillance, Epidemiology, and End Results (SEER) program provides information on cancer statistics that underpins efforts to reduce the cancer burden among the U.S. population. Learn more about the SEER program. SEER is supported by the Surveillance Research Program (SRP) in NCI's Division of Cancer Control and Population Sciences (DCCPS).
SRP provides national leadership in the science of cancer surveillance as well as analytical tools and methodological expertise in collecting, analyzing, interpreting, and disseminating reliable population-based.
This session has been automatically logged out as a result. Surveillance is an essential component of an effective infection prevention and control program. This chapter discusses the history, evolution, and use of surveillance programs in healthcare settings.
Association for Professionals in Infection Control and Epidemiology Breast cancer incidence is increasing among Asian Indian and Pakistani women living in the United States. We examined the characteristics of breast cancer in Asian Indian and Pakistani American (AIPA) and non‐Hispanic white (NHW) women using data from the surveillance, epidemiology and end results (SEER) program.
Additional Physical Format: Online version: SEER, Surveillance, Epidemiology, and End Results Program. [Bethesda, Md.]: National Institutes of Health, National.
The Surveillance, Epidemiology, and End Results (SEER) database is a publicly available, federally funded cancer reporting system that represents a collaboration between the US Centers for Disease Control and Prevention, the National Cancer Institute, and regional and state cancer registries.
1 SEER data are national, with information from 18 states that represent all regions of the country. A data linkage between the Surveillance Epidemiology and End Results (SEER) cancer registry and the Medicare Health Outcomes Survey (MHOS) was created through a partnership between the National Cancer Institute and the Centers for Medicare and Medicaid Services that created the opportunity to examine PROs in Medicare Advantage enrollees with.
Reply to The Women's Health Initiative; hormone replacement therapy; and surveillance, epidemiology, and end results data. The SEER Program is the centerpiece of these activities, with various surveillance and research functions arrayed around it to take full advantage of its potential.
The SEER Program is a sequel to two earlier NCI programs, the End Results Program and the Third National Cancer Survey. Case ascertainment and data collection for the SEER Program. The Surveillance, Epidemiology, and End Results (SEER) program is an authoritative source of information on cancer incidence and mortality in the United States.
SEER collects and publishes cancer data from a set of 17 population-based regional cancer registries located throughout the country. NCI, the Centers for Medicare and Medicaid Services, and the SEER staff have great appreciation for the potentially sensitive nature of data about persons with cancer and the need to respect the privacy of patients and providers included in the SEER-Medicare data.
First, these studies used Medicare-linked Surveillance, Epidemiology, and End Results (SEER) data and therefore included only patients aged 65 years and older. 6–8 In the United States, more than 30% of individuals with lung cancer are younger than 65 years.
10 Second, most of these studies reported data from the s, a time frame that may. Recommend-A-Book; Renew Books; Scan and Deliver; About. Events and Exhibitions; News; Directory; Facilities; Jobs; Publications; Office of the Dean; Facts & Figures; Surveillance, Epidemiology and End Results (SEER) Surveillance, Epidemiology and End Results (SEER).
Incidence patterns for ependymoma: a surveillance, epidemiology, and end results study J Neurosurg. Apr;(4) doi: /JNS Authors Courtney S McGuire 1, Kristin L Sainani, Paul G Fisher.
Affiliation 1 Department of Neurology. Methods: Patients with PNSSCC reported to the Surveillance, Epidemiology, and End Results (SEER) Program from through were categorized by sex, age, year of diagnosis, primary site, stage, and treatment.
The incidence and survival were then compared across different demographic and disease-related categories by calculating rate ratios. About patients with SCA and 1, patients with SCE were analyzed using the Surveillance, Epidemiology, and End Results database.
For grade 1, 2, 3 and 4 SCA, the 5-year OS 70, 28 and 14%; the 5-year CSS 77, 36 and 20%. METHODS: Patients with N2-III NSCLC receiving surgery between to were included using the Surveillance, Epidemiology and End Results (SEER) database.
Cox proportional hazards models were used to identify risk factors associated with overall survival (OS) and non-cancer mortality. The Kaplan-Meier method with log-rank tests was used to. Methods and Materials. Data were obtained from the Surveillance, Epidemiology, and End Results (SEER) program between and The.
The study population consisted of patients in the Surveillance, Epidemiology and End Results (SEER) Program database diagnosed with PCa between and Patients were assigned to the following clinical risk groups: low-risk localised (LRL), intermediate-risk localised (IRL), high-risk localised (HRL), node-positive and metastatic (M1).
Visit the SEER Training Website to access web-based training modules for cancer registration and surveillance. The training modules on this site are funded by the U.S.
National Cancer Institute's Surveillance, Epidemiology and End Results (SEER) Program. If so, this would be reflected in a downward stage shift, with an increase in the incidence of stage IA PDAC being diagnosed.
We analyzed data from the Surveillance, Epidemiology and End Results (SEER) registry, representative of the US population, to assess recent trends in the stage of newly diagnosed PDACs, age at diagnosis, and survival. Get this from a library. Informational guidebook training aids: cancer surveillance, epidemiology and end results reporting.
[Paula Baylis]. Background: Thyroid cancer incidence has continuously increased for decades and the causes of this increase are still controversial. The objective of this study was to examine if the increased trend is different among the different National Cancer Institute (NCI) Race/Ethnicity Groups (REGs) within the NCI surveillance epidemiology and end results database for the United States.
The authors acknowledge the efforts of the Surveillance, Epidemiology, and End Results (SEER) Program tumor registry. Footnotes. Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication.
As a service to our customers we are providing this early version of the manuscript. METHODS Using the Surveillance, Epidemiology, and End Results (SEER) Program () database, the authors identified patients with WHO Grade II oligodendroglioma (O2 group) and patients with WHO Grade III oligodendroglioma (O3 group).
Resection was defined as GTR, subtotal resection, biopsy only, or no resection. The Surveillance, Epidemiology, and End Results Program (SEER) tracks the incidence of persons diagnosed with cancer during the year and collects follow-up information on all previously diagnosed patients until their death.
Population Covered. As ofSEER registries cover. We analyzed Surveillance, Epidemiology, and End Results (SEER)‐Medicare data women diagnosed between and with ductal carcinoma in situ and stage I‐II breast cancer.
By using diagnosis and procedure codes from 3 months before to 6 months after the SEER diagnosis, we classified the initial biopsy as needle or surgical. The surveillance, epidemiology, and end results (SEER) database (National Cancer Institute) was queried with SEER*Stat software for EC cases.
The years of diagnosis were set to – The screening parameters were set as primary tumor site (esophageal), adults (age. Question: Questions Use The Following Information: A Study From Used Surveillance, Epidemiology, And End Results (SEER) Data To Ident Men Diagnosed With Testicular Cancer From To The Investigators Examined Whether The Men's Insurance Status At Time Of Diagnosis Predicted Their Risk Of Death During The Following Five Years.